Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Fimecs, a Japan-based proteolysis inducer screening platform developer, has raised ¥1.18bn ($10.3m) in series B funding from Kyoto University’s Innovation Capital unit and University of Tokyo’s Innovation Platform’s AOI Fund 1 as well as insurer Nippon Life’s Nissay Capital vehicle and venture capital firm Anri. AOI Fund had already backed a $1.9m round in 2020.…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.